Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19).
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 33097604.
- Also identified by DOI 10.1136/thoraxjnl-2020-215705.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
False negatives from nasopharyngeal swabs (NPS) using reverse transcriptase PCR (RT-PCR) in SARS-CoV-2 are high. Exhaled breath condensate (EBC) contains lower respiratory droplets that may improve detection. We performed EBC RT-PCR for SARS-CoV-2 genes (E, S, N, ORF1ab) on NPS-positive (n=16) and NPS-negative/clinically positive COVID-19 patients (n=15) using two commercial assays. EBC detected SARS-CoV-2 in 93.5% (29/31) using the four genes. Pre-SARS-CoV-2 era controls (n=14) were negative. EBC was positive in NPS negative/clinically positive patients in 66.6% (10/15) using the identical E and S (E/S) gene assay used for NPS, 73.3% (11/15) using the N/ORF1ab assay and 14/15 (93.3%) combined.
Medical subject headings
- Breath Tests
- COVID-19
- COVID-19 Testing
- Exhalation
- RNA, Viral
- SARS-CoV-2